Alpha-MSH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-09. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Statistical analysis of voting asserted that despite continued counting, the projections were already set and new ballots would not sway the outcomes of any of the states and D.C. The Cybersecurity and Infrastructure Security Agency director Jen Easterly refuted the false claims, and wrote in a statement that there was "no evidence of any malicious activity that had a material impact on the security or integrity of our election infrastructure". Another false claim alleges Musk used the satellite Internet constellation Starlink to change the results of the election. Chief technology officer Chip Trowbridge of voting system manufacturer Clear Ballot dismissed the claim and added that no machines used to scan voting ballots have any network connection whatsoever.
From the 1950s onward, lobotomy began to be abandoned, first in the Soviet Union, where the procedure immediately garnered extensive criticism and was not widely employed, before being banned in December 1950, and then Europe. Derivatives of it such as stereotactic tractotomy and bilateral cingulotomy are still used.
== Biography == Richardson was born on January 25, 1941, and grew up in Teaneck, New Jersey. Her father was an electrical engineer and her mother was an English teacher. Her parents encouraged an interest in science and she was a member of local astronomy clubs as early as elementary school. She attended Teaneck High School and in 1958 won third place in the Westinghouse Science Talent Search, the most prestigious science fair in the United States, with calculations of the satellite Sputnik's orbit from her own observations. She continued her education intending to study mathematics, astronomy and physics at Swarthmore College. However, Richardson instead graduated Phi Beta Kappa with a bachelor's degree in philosophy and a minor in physics in 1962 before she pursued graduate work in philosophy at Harvard University. Meanwhile, she was able to enroll in plant taxonomy and evolution courses at Harvard that would later contribute to her big-picture approach to studying protein structure. Since Harvard's philosophy focused on modern philosophy instead of Richardson's interest, classical philosophy, Richardson left with her master's degree from Harvard in 1966. Post-graduation, Richardson tried teaching high school, but soon realized that this career path was not for her. She subsequently rejoined the scientific world, working as a technician at Massachusetts Institute of Technology in the same laboratory as her husband, David Richardson, whom she met at Swarthmore College.
== Signs and symptoms == Disease severity varies greatly, even between family members with identical mutations. Age of onset is highly variable, although symptoms usually appear between 8 and 15 years of age. Patients usually lose the ability to ambulate 10 – 20 years after symptoms appear. Milder forms present with symptoms other than weakness, such as muscle aches, cramps, or exercise intolerance, and people in this group can retain ambulation beyond age 60. Weakness is symmetric, progressive, and proximal (on or close to the torso), usually affecting the hip girdle and shoulder girdle muscles. Hip weakness can manifest as a waddling gate. Shoulder weakness can manifest as winged scapulas. Muscle contractures, especially of the Achilles tendon, and scoliosis can also occur. Heart function and intelligence are generally not affected. Additionally, the muscles of the face, eye, tongue, and neck are spared.
Sources: en.wikipedia.org
Thomas first travelled to the United States in the 1950s; his readings there brought him a degree of fame, while his erratic behaviour and drinking worsened. During his fourth trip to New York in 1953, Thomas became gravely ill and fell into a coma. He died on 9 November, and his body was returned to Wales. On 25 November, he was interred at St. Martin's churchyard in Laugharne, Carmarthenshire. Appraisals of Thomas's work have noted his original, rhythmic and ingenious use of words and imagery. Further appraisals following on from new critical editions of his poems have sought to explore in more depth his unique modernist poetic, setting aside the distracting legend of the "doomed poet", and seeking thereby to emphasise his status as a major poet of the 20th century.
=== Projects === Focke-Wulf 1000x1000x1000 – series of bomber designs, 1944. Focke-Wulf Project I – single-seat jet fighter, 1943. Focke-Wulf Project II Focke-Wulf Project III Focke-Wulf Project VII "Flitzer" – fighter project, 1944. Focke-Wulf Project VIII – turboprop powered fighter-bomber project, also designated Fw 281 Focke Rochen – 1950s VTOL fighter project Focke-Wulf Super Lorin – Ramjet-rocket combo powered fighter Focke-Wulf Fw 354 Triebflügel – tail-sitter VTOL interceptor design Focke-Wulf TO Project Focke-Wulf Volksjäger – rocket-powered interceptor fighter project Focke-Wulf VTOL Project
== Somatostatin receptor agonists versus antagonists in radiolabelling == Agonists of the somatostatin receptor had been long established as an imaging agent, with the first agonist Ga-DOTATOC coming out in 2001, which is based on a radiolabeled somatostatin receptor agonist drug octreotide, and further developments were based on its structure. Agonists share the characteristic of being uptaken into tumor cells, and degraded intracellularly. Antagonists, while not widely absorbed into the tumor cells, can bind to a wider range of receptors as they can bind to the receptors regardless if the receptors are activated or inactivated. They thus are more sensitive to neuroendocrine tumors. Another study noted the antagonists showed lowered internalization into tumors, cleared from the blood quickly, and had a higher binding to tumors, which were noted to be properties benefitting its use over agonists in detecting metastatic tumors. A head-to-head study of the gallium-containing compounds, where the Ga-NODAGA-JR11 antagonist and Ga-DOTATOC agonist are directly compared, showed that Ga-NODAGA-JR11 had higher hepatic metastatic tumor detection rate and lesion sensitivity than Ga-DOTATOC. Another head-to-head study of lutetium containing compound found the antagonist Lu-DOTA-JR11 bound with the receptors more quickly, had a longer retention time and unbound more slowly than the Lu-DOTA-TATE agonist.
The original SAS selection course was created by John Woodhouse in 1952. The United Kingdom Special Forces do not recruit directly from the general public. All current members of the UK Armed Forces can apply for Special Forces selection, but the majority of candidates have historically come from a Royal Marines or Parachute Regiment background. Selections are held twice a year, once in summer and again in winter. Typically only 10% of candidates make it through the initial selection process. Between 2014 and 2022 there were more deaths in training and exercises than in combat against armed threats. In a group of approximately 200 candidates, most will drop out within the first few days, and fewer than 30 will remain by the end. Those who complete all phases of selection are transferred to an operational squadron. For applicants to the reserve component, 21 SAS and 23 SAS, the pathway involves comparable elements, apart from jungle training, but taken in blocks, spread out over a longer period, to fit in with the demands of participants' civilian careers. In October 2018, recruitment policy changed to allow women to become members of the SAS for the first time. In August 2021, two women became the first to pass the pre-selection course, making them eligible for the full course. The first phase of selection, aptitude phase, lasts 4 weeks and takes place in the Brecon Beacons. This phase also involves training in Sennybridge, and normally starts with approximately 200 potential candidates.
=== Occurrence === GGC occurs in human plasma in the range of 1 to 5 μM and intracellularly at 5 to 10 μM. The intracellular concentration is generally low because GGC is rapidly bonded with a glycine to form glutathione. This second and final reaction step in glutathione biosynthesis is catalysed by the activity of the ATP dependent glutathione synthetase enzyme.
Sources: en.wikipedia.org
==== MeSH E05.598.500 – disease models, animal ==== MeSH E05.598.500.249 – arthritis, experimental MeSH E05.598.500.374 – diabetes mellitus, experimental MeSH E05.598.500.468 – liver cirrhosis, experimental MeSH E05.598.500.496 – neoplasms, experimental MeSH E05.598.500.496.500 – leukemia, experimental MeSH E05.598.500.496.750 – liver neoplasms, experimental MeSH E05.598.500.496.843 – mammary neoplasms, experimental MeSH E05.598.500.496.937 – melanoma, experimental MeSH E05.598.500.496.968 – sarcoma, experimental MeSH E05.598.500.500 – nervous system autoimmune disease, experimental MeSH E05.598.500.500.500 – encephalomyelitis, autoimmune, experimental MeSH E05.598.500.500.750 – myasthenia gravis, autoimmune, experimental MeSH E05.598.500.500.875 – neuritis, autoimmune, experimental MeSH E05.598.500.750 – radiation injuries, experimental
==== Cancer ==== The first study on trained dogs used for the detection of cancer was published by Willis et al. in 2004, observing that dogs were capable of detecting bladder cancer from urine samples. Subsequently, in 2004, Pickel et al. confirmed that dogs were able to successfully diagnose melanoma. In 2008, Horvath et al. confirmed dogs were successful in differentiating between cancerous and normal tissue and in distinguishing non-cancerous pathological tissue from cancerous tissue. Another study by Horvath et al. in 2010 found the dogs to show over 90% specificity in detecting ovarian cancer from blood samples, colorectal cancer from respiratory air, and prostate cancer from dog urine.
=== Variable contact rates === It is well known that the probability of getting a disease is not constant in time. As a pandemic progresses, reactions to the pandemic may change the contact rates which are assumed constant in the simpler models. Counter-measures such as masks, social distancing, and lockdown will alter the contact rate in a way to reduce the speed of the pandemic. In addition, Some diseases are seasonal, such as the common cold viruses, which are more prevalent during winter. With childhood diseases, such as measles, mumps, and rubella, there is a strong correlation with the school calendar, so that during the school holidays the probability of getting such a disease dramatically decreases. As a consequence, for many classes of diseases, one should consider a force of infection with periodically ('seasonal') varying contact rate
There are actually two very closely related compounds commonly referred to as eosin. Most often used is in histology is eosin Y, which is a tetra-bromo derivative of fluorescein and has a very slightly yellowish cast. It is also known as eosin Y ws, eosin yellowish, Acid Red 87, C.I. 45380, bromoeosine, bromofluoresceic acid, and D&C Red No. 22. The other eosin compound is eosin B, which is a dibromo derivative and has a very faint bluish cast. It is also known as eosin bluish, Acid Red 91, C.I. 45400, Saffrosine, Eosin Scarlet, and imperial red. The two dyes are interchangeable, and the use of one or the other is a matter of preference and tradition. Food dye tetraiodofluorescein was historically known as Bluish Eosine, Eosin J or iodo-eosine but is now called erythrosine or Red 3.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.